Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Toku Eyes

Request full access

AI-powered retinal imaging for systemic health assessment

Auckland, New ZealandFounded 2018Health Tech & Medtech

About Toku Eyes

Toku Eyes is a health technology company that utilizes artificial intelligence to analyze retinal images for early detection and risk assessment of chronic diseases. The company was founded in 2018 as a spin-out from the University of Auckland by Associate Professor Ehsan Vaghefi and Dr. David Squirrell. Vaghefi's personal experience with his father's preventable blindness from congenital glaucoma fueled his mission to make disease screening more accessible.

The company's core business revolves around its AI platform that integrates with existing retinal cameras to provide rapid, non-invasive health assessments. This makes screening possible in various point-of-care settings like optometry clinics, primary care, and pharmacies. Toku's business model involves strategic partnerships with major industry players, such as optical retailers and ophthalmic device manufacturers, to deploy its software. For example, partnerships with National Vision and Topcon Healthcare are set to make them significant customers, integrating Toku's platform into their networks.

Toku offers several products. 'BioAge' analyzes biometric markers in the retina to determine a person's biological age as an indicator of overall health. The 'CLAiR' platform assesses cardiovascular disease (CVD) risk and has received Breakthrough Device designation from the U.S. FDA, which expedites its review process. Another product, 'MyKidneyAI', also granted FDA Breakthrough status, screens for chronic kidney disease risk in people with diabetes. These tools are designed to identify at-risk individuals early, allowing for timely preventative interventions.

Since its inception, Toku Eyes has secured significant funding, including a $3.6 million seed round and a US$8 million Series A round in April 2023, bringing its total to over $10.5 million. The company has expanded its team and is focused on commercialization in North America and other global markets, with regulatory approvals already secured in the UK and Europe.

Source: Dealroom company data

Toku Eyes in the Auckland ecosystem

Live from Dealroom

The Toku Eyes office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed4 investors entered at this stage

  • Artemis Capital
  • Icehouse Ventures
  • Kera Link International
  • Callaghan Innovation

Series A2 investors entered at this stage

  • National Vision
  • Topcon Healthcare
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇳🇿 New Zealand72.2%
🇺🇸 United States27.8%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Toku Eyes on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Toku Eyes on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.